



Pfizer Announces a Quality Improvement Grant RFP

Optimal Early Therapy Management in CML

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

II. Eligibility

Geographic Scope:	United States and Canada
Applicant Eligibility Criteria	<ul style="list-style-type: none">The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; and other entities with a mission related to healthcare improvement.If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.For projects offering continuing education credit, the requesting organization must be accredited.

III. Requirements

Date RFP Issued	<ul style="list-style-type: none">July 14 2020
Clinical Area	<ul style="list-style-type: none">Oncology – Hematology – Chronic Myelogenous Leukemia (CML)
General Area of Interest for this RFP:	<p>The aim of this RFP is to support three Quality Improvement (QI) Projects that will enhance systems of care or implement new tools that will optimize early therapy management for patients with CML.</p> <p>The intent of the RFP is to support one project in Canada and two in the United States.</p> <p><u>Proposals should:</u></p> <ul style="list-style-type: none">Engage a multi-disciplinary team to identify and implement improvements in systems of careIncorporate patient's perspectives and participation in CML therapy managementDevelop QI tools to support clinicians / patients in first ~90 days of TKI treatment for patientsEstablish a plan for widely sharing best practices and QI tools that

come from the project

Background:

- Patient support and early therapy management are essential for patients with CML since TKI discontinuation may lead to inferior outcomes
- Increased use of telehealth due to COVID-19 may mean patients are monitored less frequently and lack support, which could lead to sub-optimal therapy management and increased early discontinuation
- CML is treated by both clinical experts and general clinicians. Greater understanding is needed to appreciate the different safety profiles of the TKI agents that are available.
- Optimal management of early adverse events is needed through enhanced systems of care.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Information on how to submit requests for support of clinical research projects can be found at www.Pfizer.com/isr.

Target Audience:

- Hematology oncologists, medical oncologists, nurses, nurse practitioners, physician assistants, pharmacists

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$150,000 will be considered. The estimated total available budget related to this RFP is \$450,000

Key Dates:

- RFP release date: July 14, 2020
- Grant Application due date: October 1, 2020
Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5).
- Anticipated Grant Award Notification Date: November 2, 2020
**Processing time may take longer for organizations outside of the U.S.*
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: 1-year projects, approximately January 2021 to January 2022



How to Submit:	<ul style="list-style-type: none">• Please go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click “Create your password”.• In the application:<ul style="list-style-type: none">◦ For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes◦ Select the following Competitive Grant Program Name: 2020 Oncology: Optimal Early Therapy Management in CML◦ Select the following Primary Area of Interest: Oncology – Hematology - CML• Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the Full Proposal Submission field.• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.</p>
Questions:	<ul style="list-style-type: none">• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jackie Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line “Optimal Early Therapy Management in CML.”
Review and Approval Process	<ul style="list-style-type: none">• Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
Mechanism by which Applicants will be Notified:	<ul style="list-style-type: none">• All applicants will be notified via email by the dates noted above.• Applicants may be asked for additional clarification during the review period.

Appendix A

Quality Improvement Project Full Proposal

Applications will be accepted via the online portal. Full Proposal documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal please ensure it addresses the following*:

Goals and Objectives	<ul style="list-style-type: none"> • Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s). • List the <i>overall</i> objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.
Assessment of Need for the Project	<ul style="list-style-type: none"> • Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in <i>your</i> target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.
Target Audience	<ul style="list-style-type: none"> • Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods	<ul style="list-style-type: none"> • Describe the planned project and the way it addresses the established need. • If your methods include educational activities, please describe succinctly the topic(s) and format of those activities
Innovation	<ul style="list-style-type: none"> • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. • Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
Evaluation and Outcomes	<ul style="list-style-type: none"> • In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data. • Quantify the amount of change expected from this project in terms of your target audience.

	<ul style="list-style-type: none">• Describe how the project outcomes will be broadly disseminated.
Anticipated Project Timeline	<ul style="list-style-type: none">• Provide an anticipated timeline for your project including project start/end dates
Additional Information	<ul style="list-style-type: none">• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here
Organization Detail	<ul style="list-style-type: none">• Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

*The online application also includes the fields noted above. The text in those fields should be the same text that is included in your Full Proposal document.